the annexa-a and annexa-r trials
Published 8 years ago • 7.8K plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
27:51
direct-acting oral anticoagulants (doacs) | moa , indications, adverse reactions, contraindications
-
1:12
what are my options for anticoagulation therapy for atrial fibrillation?
-
8:14
alligations with converions
-
6:39
direct oral anticoagulants made easy (mnemonics, mechanism of action, side effects, counseling)
-
13:45
doacs vs warfarin - when to use one vs the other
-
1:50
treating patients with poor-risk cytogenetics with venetoclax and hmas
-
19:07
doacs: anticoagulation principles - part 1: background, mechanism, and uses
-
47:41
faqs: anticoagulation in primary care for stroke prevention in af
-
50:18
direct oral anticoagulation therapy for vte at extremes of body weight
-
17:58
direct oral anticoagulants (doac): a review
-
3:08
esc tv at acc.17 - re-circuit: uninterrupted anticoagulation with dabigatran etexilate vs warfarin
-
25:02
new oral anticoagulants
-
16:09
doacs in the anticoagulant treatment landscape
-
3:04
should atrial fibrillation patients take oral anticoagulants?
-
1:08
ame minute: new oral anticoagulants in the dvt protocol
-
3:22
risk factors for oral anticoagulant-associated ich
-
1:14
challenges of using doacs in everyday practice - cardioed lecture
-
20:18
patient pulse: the patient's guide to doac reversal
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
3:42
from soup to nuts: how to diagnose axspa in clinical practice